INS and diabetes mellitus: Another study examined the effects of 12 week MO treatment (500 mg three times/day) in DM patients, finding significant plasmatic reductions in both HbA1C levels and high specificity C-reactive protein [81], however, this study has serious limitations, which included not reporting the changes in blood glucose or insulin, no randomization or blinding in study design, not specifying the type of diabetes of participants, and having a very large age distribution, among others.